Skip to main content

Table 5 Univariate and multivariate Cox regression analysis for GBM cohort (n = 453)

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

  Univariate Multivariate
OS PFS OS PFS
HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value
Cohort Cohort 1 0.81 0.643–1.030 0.09 1.11 0.884–1.398 0.37 excluded by factor selection with step-wise method excluded by factor selection with step-wise method
Cohort 2 Ref Ref
Location Cerebrum 0.91 0.504–1.624 0.74 0.81 0.489–1.357 0.43 excluded by factor selection with step-wise method excluded by factor selection with step-wise method
Cerebrum with Frontal Involvement 0.93 0.511–1.705 0.82 0.78 0.458–1.317 0.35
  Other Ref Ref
Age   1.015a 1.004–1.025 0.006 1.004a 0.995–1.013 0.38 1.01a 1.004–1.025 0.008 excluded by factor selection with step-wise method
Sex M Ref Ref excluded by factor selection with step-wise method excluded by factor selection with step-wise method
  F 0.72 0.570–0.918 0.008 0.78 0.621–0.975 0.03
KPS   0.992b 0.985–0.999 0.03 0.999b 0.992–1.006 0.74 0.99b 0.982–0.997 0.009 excluded by factor selection with step-wise method
Surgery Biopsy 2.59 1.725–3.899 <0.0001 2.06 1.349–3.130 0.0008 3.15 2.082–4.769 <0.0001 2.22 1.454–3.380 0.0002
  Removal Ref Ref Ref Ref
TERT wild-type 0.73 0.568–0.925 0.01 0.73 0.581–0.922 0.008 Interacts with MGMT <0.0001 0.65 0.513–0.821 0.0003
  mutated Ref Ref   Ref
MGMT Methylated 0.43 0.325–0.561 <0.0001 0.51 0.396–0.656 <0.0001 Interacts with TERT <0.0001 0.48 0.368–0.613 <0.0001
  Unmethylated Ref Ref   Ref
TERT-MGMT TERT-MGMT interaction    0.006 excluded by factor selection with step-wise method
  Wt/Met 0.32   
  Mut/Met 0.27   
  Wt/Un-met 0.54   
  Mut/Un-met Ref   
  1. Chemo Chemotherapy, C.I. Coefficient interval, CRT chemoradiotherapy, F Female, GBM glioblastoma, HR hazard ratio, KPS Karnofsky Performance status, M Male, Met MGMT methylated, Mut TERT mutated, OS overall survival, PFS progression free survival, Ref Reference, RT radiation therapy, Un-met MGMT unmethylated, Wt TERT wild-type
  2. aHR is for each one year increase
  3. bHR is for each 1 % increase